Skip to main
  1. Stocks
  2. Helus Pharma Inc
  3. Forecast
HELP

HELP Stock Forecast & Price Target

HELP Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Helus Pharma is viewed positively because HLP003 has completed enrollment in the Phase 3 APPROACH adjunctive MDD study, with topline data due around mid-Nov and a prior Phase 2 result showing a ~13-point placebo-adjusted MADRS improvement, supporting meaningful de-risking of the lead program. Its outlook is also strengthened by HLP004, which posted about a 10-point HAM-A reduction in GAD and could open a second large market, while 2Q26 R&D of $28.9MM, G&A of $13.7MM, and $157.3MM in cash, plus a $50MM financing, suggest adequate funding into the next readout. Additional support comes from a seasoned neuropsychiatry CEO, improving regulatory and M&A sentiment, and external validation of psychedelic mechanisms that enhances confidence in both pipeline and strategic value.

Bears say

Helus Pharma is viewed negatively because its value proposition remains highly speculative, with HLP003 and HLP004 still in clinical development and subject to meaningful execution, regulatory, and commercialization risk. Although cash increased to $157.3 million as of March 31 and a $50 million raise closed on June 25, 2026, the model still assumes annual equity raises of $150 million in FY2027E-FY2029E, highlighting likely dilution and continued dependence on capital markets. The outlook is further pressured by delayed launch timing for HLP003 to F2029E and HLP004 to F2030E, alongside reduced asset valuations to $52/share and $18/share and a lower total firm value of about $5.6 billion.

HELP has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Helus Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

HELP Analyst Forecast & Price Prediction

Get the latest HELP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HELP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Helus Pharma Inc (HELP) Forecast

Analysts have given HELP a Strong Buy based on their latest research and market trends.

According to 6 analysts, HELP has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Helus Pharma Inc (HELP)


HELP Analyst Forecast & Price Prediction

Get the latest HELP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HELP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HELP stock data and trends